https://jfinnova.es Curated analysis of discoveries, regulations, and industry movements shaping neuroinflammation therapeutics. en Wed, 09 Apr 2026 00:00:00 GMT https://jfinnova.es/news/microglial-cd74-ms-disability Researchers at the University of Zurich have published landmark single-nucleus RNA sequencing data demonstrating that CD74+ microglial density correlates directly with progressive disability accumulation in MS lesions. Wed, 01 Apr 2026 00:00:00 GMT https://jfinnova.es/news/microglial-cd74-ms-disability Target Validation https://jfinnova.es/news/sanofi-acquisitions-vhh-platforms Sanofi's strategic acquisitions of single-domain antibody platforms signal a major industry pivot toward VHH-based therapeutics, driven by their superior tissue penetration and manufacturing simplicity. Sun, 01 Mar 2026 00:00:00 GMT https://jfinnova.es/news/sanofi-acquisitions-vhh-platforms Industry https://jfinnova.es/news/ibudilast-progressive-ms-biologic The SPRINT-MS trial (MediciNova) demonstrated modest neuroprotection with ibudilast, but its non-selective MIF inhibition and off-target PDE effects highlight the ceiling of small-molecule approaches in neuroinflammation. Sun, 01 Mar 2026 00:00:00 GMT https://jfinnova.es/news/ibudilast-progressive-ms-biologic Competitive Landscape https://jfinnova.es/news/fda-2026-ai-designed-biologics The FDA's updated framework for AI/ML-designed therapeutic candidates introduces new transparency requirements for in silico design pipelines, including algorithm provenance documentation and computational reproducibility standards. Thu, 01 Jan 2026 00:00:00 GMT https://jfinnova.es/news/fda-2026-ai-designed-biologics Regulatory https://jfinnova.es/news/neotec-2026-health-ai-spain The CDTI has opened its 2026 NEOTEC call with a dedicated Health-AI track, allocating 20 million euros to support deep-tech startups developing AI-driven therapeutics and diagnostics on Spanish soil. Wed, 01 Apr 2026 00:00:00 GMT https://jfinnova.es/news/neotec-2026-health-ai-spain Funding https://jfinnova.es/news/vhh-engineering-bbb-delivery Recent publications on receptor-mediated transcytosis and single-domain antibody formats confirm that VHH nanobodies below 15 kDa achieve meaningful CNS penetration — a pharmacokinetic advantage inaccessible to conventional IgG antibodies. Sun, 01 Feb 2026 00:00:00 GMT https://jfinnova.es/news/vhh-engineering-bbb-delivery Drug Delivery https://jfinnova.es/news/human-framework-identity-vhh Anti-drug antibodies (ADA) remain the leading cause of biologic failure in late-stage clinical trials. New humanization strategies using germline framework grafting are dramatically reducing immunogenicity risk for camelid-derived nanobodies. Sun, 01 Mar 2026 00:00:00 GMT https://jfinnova.es/news/human-framework-identity-vhh Immunogenicity https://jfinnova.es/news/microglial-revolution-neurodegeneration This month's Oxford Neuroinflammation Summit highlighted microglia as the converging therapeutic target across MS, Alzheimer's, and ALS. The MIF/CD74 signaling axis was featured as a central node driving chronic neuroinflammatory activation. Wed, 01 Apr 2026 00:00:00 GMT https://jfinnova.es/news/microglial-revolution-neurodegeneration Neuroinflammation https://jfinnova.es/news/agent-based-digital-twins-phase1 Agent-based modeling (ABM) is emerging as a critical tool for preclinical de-risking. By simulating immune cell dynamics in silico, research teams can predict therapeutic outcomes before animal studies, reducing costs by up to 40%. Sun, 01 Mar 2026 00:00:00 GMT https://jfinnova.es/news/agent-based-digital-twins-phase1 Digital Twin https://jfinnova.es/news/risk-sharing-co-development-biotech The traditional VC-funded biotech model is being challenged by co-development partnerships where startups and CROs share risk, IP, and milestones. Companies like ProteoGenix are pioneering this approach with computational biotechs. Wed, 01 Apr 2026 00:00:00 GMT https://jfinnova.es/news/risk-sharing-co-development-biotech Partnering https://jfinnova.es/news/alphafold3-protein-complex-drug-design DeepMind's release of AlphaFold 3 enables prediction of protein-protein, protein-ligand, and protein-nucleic acid complexes. The structural biology community is racing to integrate these capabilities into drug discovery pipelines. Sun, 01 Mar 2026 00:00:00 GMT https://jfinnova.es/news/alphafold3-protein-complex-drug-design Industry https://jfinnova.es/news/ema-guidance-ai-generated-biologics The European Medicines Agency has released its first regulatory framework specifically addressing AI-designed biological therapeutics, establishing documentation requirements for computational design provenance and in silico validation evidence. Sun, 01 Mar 2026 00:00:00 GMT https://jfinnova.es/news/ema-guidance-ai-generated-biologics Regulatory https://jfinnova.es/news/cablivi-vhh-billion-dollar-validation Sanofi's caplacizumab (Cablivi), the first FDA-approved VHH nanobody, has crossed the $1 billion annual revenue milestone, proving that single-domain antibodies are not just a research curiosity but a commercially viable therapeutic modality. Sun, 01 Feb 2026 00:00:00 GMT https://jfinnova.es/news/cablivi-vhh-billion-dollar-validation Industry https://jfinnova.es/news/spain-computational-drug-discovery-growth Spain's National Statistics Institute reports a dramatic surge in computational biology startups, driven by EU recovery funds, CDTI NEOTEC grants, and a growing ecosystem of bioinformatics talent emerging from institutions like the BSC, CNIO, and CRG. Thu, 01 Jan 2026 00:00:00 GMT https://jfinnova.es/news/spain-computational-drug-discovery-growth Funding https://jfinnova.es/news/cd74-als-cerebrospinal-fluid-biomarker A multi-center proteomics study published in Nature Neuroscience identifies soluble CD74 fragments as a robust biomarker in ALS patient cerebrospinal fluid, correlating with disease progression and microglial activation state. Wed, 01 Apr 2026 00:00:00 GMT https://jfinnova.es/news/cd74-als-cerebrospinal-fluid-biomarker Target Validation